JP2016501209A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501209A5
JP2016501209A5 JP2015544459A JP2015544459A JP2016501209A5 JP 2016501209 A5 JP2016501209 A5 JP 2016501209A5 JP 2015544459 A JP2015544459 A JP 2015544459A JP 2015544459 A JP2015544459 A JP 2015544459A JP 2016501209 A5 JP2016501209 A5 JP 2016501209A5
Authority
JP
Japan
Prior art keywords
compound
dichloropyridin
composition according
inflammatory
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015544459A
Other languages
English (en)
Japanese (ja)
Other versions
JP6367819B2 (ja
JP2016501209A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/074958 external-priority patent/WO2014083099A1/en
Publication of JP2016501209A publication Critical patent/JP2016501209A/ja
Publication of JP2016501209A5 publication Critical patent/JP2016501209A5/ja
Application granted granted Critical
Publication of JP6367819B2 publication Critical patent/JP6367819B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015544459A 2012-11-30 2013-11-28 活性化ｔ細胞におけるｉｌ−２２の発現の阻害方法 Expired - Fee Related JP6367819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731867P 2012-11-30 2012-11-30
US61/731,867 2012-11-30
PCT/EP2013/074958 WO2014083099A1 (en) 2012-11-30 2013-11-28 A method of inhibiting the expression of il-22 in activated t-cells

Publications (3)

Publication Number Publication Date
JP2016501209A JP2016501209A (ja) 2016-01-18
JP2016501209A5 true JP2016501209A5 (enExample) 2017-01-05
JP6367819B2 JP6367819B2 (ja) 2018-08-01

Family

ID=49681024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544459A Expired - Fee Related JP6367819B2 (ja) 2012-11-30 2013-11-28 活性化ｔ細胞におけるｉｌ−２２の発現の阻害方法

Country Status (6)

Country Link
US (1) US9855285B2 (enExample)
EP (1) EP2925364A1 (enExample)
JP (1) JP6367819B2 (enExample)
CN (1) CN104822392B (enExample)
RU (1) RU2663448C2 (enExample)
WO (1) WO2014083099A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
FR3071508B1 (fr) * 2017-09-26 2022-07-29 Genoskin Modele ex vivo de peau humaine inflammee et ses utilisations pour le criblage de composes anti-inflammatoires
EP3853204A4 (en) * 2018-09-21 2022-06-22 Apramitha Innovations Private Limited IMPROVED AND STABLE APREMILAST PHARMACEUTICAL COMPOSITIONS
JP2022518292A (ja) * 2019-01-23 2022-03-14 パス セラピューティクス，インク． ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US20210212962A1 (en) * 2020-01-13 2021-07-15 Sol-Gel Technologies Ltd. Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases
CN116919958A (zh) * 2023-07-05 2023-10-24 南方医科大学口腔医院 罗氟司特在骨缺损修复治疗中的应用
WO2025221488A1 (en) * 2024-04-16 2025-10-23 Alto Neuroscience, Inc. Transdermal administration of pde4 inhibitors for reduction in adverse events

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123726A1 (ja) * 2005-05-18 2006-11-23 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
AU2007336538B2 (en) * 2006-12-22 2012-04-05 Leo Pharma A/S Substituted acetophenones useful as PDE4 inhibitors
KR101571654B1 (ko) * 2007-02-28 2015-11-25 레오 파마 에이/에스 신규한 포스포디에스테라제 억제제
CA2688670A1 (en) * 2007-04-19 2008-10-30 Leo Pharma A/S Src family kinase inhibitors
SG172206A1 (en) * 2008-12-19 2011-07-28 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
US20120322776A1 (en) 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
NZ603895A (en) * 2010-06-24 2014-10-31 Leo Pharma As Novel phosphodiesterase inhibitors

Similar Documents

Publication Publication Date Title
NO20076561L (no) Imidazoquinoliner som lipid kinaseinhibitorer
HRP20191136T1 (hr) Derivati benzodioksola kao inhibitori fosfodiesteraze
JP2014527996A5 (enExample)
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
CR8918A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
RU2015125680A (ru) Способ ингибирования экспрессии ил-22 активированными т-клетками
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
DK1485080T3 (da) Anvendelse af adapalen til behandling af dermatologiske sygdomme
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
JP2015524816A5 (enExample)
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
HRP20100616T1 (hr) Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa
TN2012000139A1 (en) Cgrp receptor antagonists
PE20150710A1 (es) Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion
JP2015531396A5 (enExample)
DK2105164T3 (da) Nye P2X7R-antagonister og deres anvendelse
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
PE20181274A1 (es) Compuestos utiles para inhibir ror-gamma-t
PL3439660T3 (pl) Stosowanie pimobendanu w celu redukowaniu wielkości serca i opóźnienia początku objawów klinicznych u pacjentów z bezobjawową niewydolnością serca w wyniku choroby zastawki mitralnej
BR112015010136A2 (pt) derivados de oxazolidin-2-ona-pirimidina
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
WO2010006189A3 (en) Small-molecule inhibitors of hif and angiogenesis
EA201491213A1 (ru) Антагонисты trpm8